[Epidermal growth factor receptors: status evaluation methods and XXXX expression].

@entity1 @entity470 @entity5 @entity358 @entity669 @entity1722
The development of targeted antitumor agent aiming the HER family of @entity669 kinase transmembrane receptors, focused on the issue of target detection. For @entity1722 , the techniques used to detect an overexpression are well established and none has, to date, shown its superiority. These are immunohistochemistry (protein) and in situ fluorescent hybridization (DNA). For @entity470 , the diversity of the activation means (amplification, mutation, enhanced transcription, ligands...) leads to technical caveats. Immunohistochemistry appears to be the most appropriate test for clinical use but standardized assays and scoring systems are mandatory. The @entity470 levels of expression are very high in some normal tissues such as oral mucosae. In @entity5 , @entity470 levels are variable. The highest expression is found in head and neck @entity5 . @entity470 expression is also elevated in @entity358 . @entity470 testing may be required before targeted treatment. An exciting endpoint would be the functional and dynamic evaluation of @entity470 and downstream proteins for @entity1 , before and during treatment.
